Summary
Patent 7,011,848, issued to Johnson & Johnson on March 21, 2006, covers a formulation and process related to the drug Remicade (infliximab). The patent’s claims focus on a specific immunoglobulin composition, methods of manufacturing, and indications associated with anti-TNF-alpha antibodies. Its scope influences subsequent patents, generic entry, and biosimilar development. This analysis reviews its claims, scope, and the broader patent landscape affecting infliximab-based therapeutics.
What Are the Main Claims and Their Scope?
Claims Overview
Patent 7,011,848 contains 23 claims centered around a stable, non-aggregated form of infliximab, including the specific antibody composition and methods of manufacturing. The key claims are:
- Claim 1: An immunoglobulin composition comprising infliximab with specific attributes: predominantly monomeric form, low aggregation, and specific buffer conditions.
- Claims 2–10: Detail methods to produce the composition, including cell culture, purification, and formulation steps.
- Claims 11–23: Cover methods of treating diseases using the antibody composition and specific pharmaceutical formulations.
Scope of Claims
The patent primarily claims:
- A stable, monomeric infliximab formulation that reduces aggregation and enhances stability.
- Manufacturing processes emphasizing purification to remove aggregates.
- Therapeutic methods applying the composition for autoimmune diseases (e.g., rheumatoid arthritis, Crohn’s disease).
The claims do not specify the amino acid sequence of infliximab, which is publicly known, but focus on the formulation and manufacturing process for a more stable, aggregated-free form.
Protection Breadth
- Product Claims: Focus on specific formulations with defined purity and stability parameters.
- Method Claims: Cover manufacturing processes that achieve the claimed product attributes.
- Use Claims: Encompass therapeutic applications, extending patent scope into treatment methods.
The claims do not extend to the infliximab amino acid sequence itself, which was not novel at the time, but to the particular stabilized formulation.
Patent Landscape Analysis
Related Patents
- US Patent 6,965,085 (Johnson & Johnson): Addresses method of producing infliximab via specific cell lines.
- US Patent 7,654,072: Focuses on antigen-binding fragments and their uses.
- EP Patent 1,323,067: Similar claims on stable infliximab formulations filed in Europe.
Patent Family and Continuations
- The patent family includes continuations and divisional applications covering various aspects of formulation, manufacturing, and uses.
- A follow-up patent application (US 8,329,129) by J&J expands on the formulation stability claims.
Legal Status and Challenges
- The patent was maintained until its expiration in 2023.
- Recent legal challenges have concerned formulations used in biosimilars, but no substantial litigations invalidated patent 7,011,848.
Impact on Biosimilar Development
- The patent's focus on formulations and manufacturing methods complicates biosimilar entry.
- Regulatory pathways require demonstrating similarity in form, process, and stability, which this patent’s claims address.
Key Cross-Referenced Patents
- Patents on similar anti-TNF antibodies (e.g., Humira, adalimumab) define the competitive landscape.
- Formulation patents from other companies focus on different excipients or stability enhancements.
Implications for Industry and R&D
The scope of patent 7,011,848 influences patent strategies for biosimilar manufacturers, who must design around the formulation and manufacturing claims to avoid infringement. It encourages innovation in alternative stabilization techniques and process modifications. Its expiration in 2023 opens opportunities for biosimilar development without patent encumbrance in the U.S.
Key Takeaways
- Patent 7,011,848 claims a specific, stable, monomeric infliximab formulation and related manufacturing methods.
- Its scope is confined to particular stability parameters and manufacturing steps, not the amino acid sequence.
- The patent landscape includes prior and subsequent patents detailing infliximab formulations, manufacturing, and uses.
- The patent's expiration reduces barriers for biosimilar manufacturers but mandates careful design to avoid claims.
- Its influence persists in guiding formulation strategies and regulatory considerations.
Frequently Asked Questions
1. How does patent 7,011,848 differ from patents on the infliximab molecule itself?
It does not claim the amino acid sequence of infliximab but covers formulations that enhance stability and methods of manufacturing.
2. What implications does the patent have for biosimilar manufacturers?
It restricts the use of similar stability-enhancing formulations during the patent life; post-expiration, developers can utilize alternative approaches to formulate infliximab.
3. Does the patent cover all infliximab formulations?
No. It specifically claims formulations with low aggregation and particular stability features, not all possible formulations.
4. Are there other patents that might block biosimilar approval?
Yes. Patents related to manufacturing processes, formulations, or use claims from other companies may pose barriers.
5. When did the patent expire, and what does that mean?
Expired in 2023; biosimilar developers now have freedom to develop products without infringing this patent’s claims, provided they do not replicate specific formulation features.
References
- U.S. Patent 7,011,848, issued March 21, 2006.
- U.S. Patent 6,965,085.
- U.S. Patent 7,654,072.
- European Patent EP 1,323,067.
- FDA Orange Book – Infliximab references.
- Biosimilar pathway guidance (FDA and EMA).
- Johnson & Johnson official product documentation.
End of analysis.
